Neil was previously Senior Vice-President, Discovery, at UCB S.A., overseeing an integrated portfolio of small molecule and antibody therapeutic projects in the areas of immunology and neurology. Neil and his teams have been responsible for transitioning 33 new chemical entities into development in immunology, oncology, bone and neurology.
Neil was one of the inventors of the drug Cimzia®, a novel pegylated anti-TNF. Prior to his role at UCB, Neil was Head of Discovery at Celltech R&D in the UK, during which time he was involved in the discovery and development of antibody and antibody fragment-based drugs including the first dual signalling domain chimeric receptor now known as second generation CAR-T.
Neil received a BSc in Biology from Edinburgh University and a PhD at the Institute of Biotechnology, University of Kent at Canterbury studying metabolic flux through amino acid biosynthesis pathways. Neil served as chair of the board of Beryllium BioSciences and is a non-exec member of the boards of the RNA Medicines company and Ondek. Neil chaired the UK ABPI innovation board from 2012 to 2018.
Olivia is a Principal at SV Health Investors and a former Partner at McKinsey and Company. She has over 15 years' experience working in healthcare and life sciences. She has led multi-year strategy and organisational efforts for biopharmaceutical, med devices and healthcare private equity clients. Olivia holds a degree in Medicine (MBChB) with honours and a first class degree in Pharmacology (BSc) from Bristol University, where she was awarded the Hans Heller Memorial Prize for outstanding performance.
Matthew joined Sitryx to lead its medicinal chemistry, CMC and intellectual property activities.
He has 19 years of experience in drug discovery and development, having formerly held positions as Head of Chemistry and Intellectual Property at TopiVert (London), Director of Drug Discovery at Oryzon (Barcelona) and Director of Medicinal Chemistry at Prosidion (Oxford). Matthew has successfully led research endeavours in multiple therapeutic areas, delivering compounds that have reached Phase 2 or further in oncology, immunology, metabolic disease, neurology and ophthalmology. Several of these compounds have been purchased by major pharma companies.
Matthew obtained degrees from the University of Glasgow (BSc), Columbia University (MA) and the University of Birmingham (PhD) prior to postdoctoral studies at UCLA with Nobel prize winner Sir Fraser Stoddart. He is a Chartered Chemist, a Fellow of The Royal Society of Chemistry, an author of more than 40 peer-reviewed publications and an inventor on over 75 patent applications.
Margaret is a Director and the CEO of Bradshaw Daniel Ltd which provides CFO and accounting services to a number of Biotech Life Science companies including GammaDelta Therapeutics, Apollo Therapeutics LLP, Storm Therapeutics Ltd and Microbiotica Ltd.
Margaret has 10 years' experience in Finance Director and CFO roles and worked in both international and UK Group companies prior to setting up Bradshaw Daniel with her business partner John Bradshaw in 2012. Margaret is a Chartered Management Accountant who also holds a certificate in Company Direction from the Institute of Directors.
Matthew is a Senior Scientist at Sitryx. Matthew has a PhD from the University of Sydney and worked as a postdoctoral researcher at the University of Oxford in the Experimental Therapeutics and Clinical Pharmacology group studying metabolism in genetic cardiovascular diseases, with a particular focus on the role of the tricarboxylic acid cycle in the pathogenesis of heart failure.
Our experienced and respected management team have a proven track record guiding new companies through early inflection points.